Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Konishi Y, Sklavenitis-Pistofidis R, Yue H, Ferrari F, Redd RA, Lightbody ED, Russo M, Perry J, Horowitz E, Justis AV, Shayegh NA, Savell A, Prescott J, Varmeh S, Nowak RP, Hamilton M, Auclair D, Marinac CR, Trippa L, Fischer ES, Ghobrial IM. Konishi Y, et al. Among authors: redd ra. Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9. Cancer Cell. 2022. PMID: 34895486 Free PMC article. No abstract available.
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS. Ghobrial IM, et al. Among authors: redd ra. Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31. Clin Cancer Res. 2020. PMID: 31672767 Clinical Trial.
Progression signature underlies clonal evolution and dissemination of multiple myeloma.
Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, Manier S, Roccaro AM, Sacco A, Tai YT, Mercier F, Kawano Y, Su NK, Berrios B, Doench JG, Root DE, Michor F, Scadden DT, Ghobrial IM. Shen YJ, et al. Among authors: redd ra. Blood. 2021 Apr 29;137(17):2360-2372. doi: 10.1182/blood.2020005885. Blood. 2021. PMID: 33150374 Free PMC article.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: redd ra. Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. Cancer Cell. 2022. PMID: 36379208 Free PMC article.
Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.
Mouhieddine TH, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, Tahri S, El-Khoury H, Steensma DP, Ebert BL, Soiffer RJ, Keats JJ, Mehr S, Auclair D, Ghobrial IM, Sperling AS, Stewart C, Getz G. Mouhieddine TH, et al. Cancer Res Commun. 2023 Dec 18;3(12):2560-2571. doi: 10.1158/2767-9764.CRC-23-0093. Cancer Res Commun. 2023. PMID: 38019104 Free PMC article.
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
Lee DJ, El-Khoury H, Tramontano AC, Alberge JB, Perry J, Davis MI, Horowitz E, Redd R, Sakrikar D, Barnidge D, Perkins MC, Harding S, Mucci L, Rebbeck TR, Ghobrial IM, Marinac CR. Lee DJ, et al. Blood Adv. 2024 Apr 9;8(7):1737-1746. doi: 10.1182/bloodadvances.2023010843. Blood Adv. 2024. PMID: 38212245 Free PMC article. Clinical Trial.
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Roemer MG, et al. Among authors: redd ra. Cancer Immunol Res. 2016 Nov;4(11):910-916. doi: 10.1158/2326-6066.CIR-16-0201. Epub 2016 Oct 13. Cancer Immunol Res. 2016. PMID: 27737878 Free PMC article.
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell E, Bianchi G, Branagan AR, Schlossman RL, Shaprio SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd RA, Lohr JG, Anderson KC, Richardson PG, Raje N. Yee AJ, et al. Among authors: redd ra. Blood Adv. 2024 Dec 3:bloodadvances.2024014717. doi: 10.1182/bloodadvances.2024014717. Online ahead of print. Blood Adv. 2024. PMID: 39626297
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA. Roemer MG, et al. Among authors: redd ra. J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069084 Free PMC article.
57 results